Search - tctmd.com

Displaying 1 - 20 of 46

Sort: Relevancy | Date

News Opinion Editor's Corner ACC 2016

Hot or Not, This Year’s Trials Offer Food for Thought: My Takeaways From ACC 2016

Shelley Wood

April 13, 2016

News Conference News ACC 2016

Toker’s Paradox? Marijuana Users Face Lower Short-Term Risks After Acute MI, Study Hints

Todd Neale

April 11, 2016

News Conference News ACC 2016

CABG Beats Medical Therapy in CAD Patients With Severe LV Dysfunction: STICH 10-Year Results

Shelley Wood

April 08, 2016

News Conference News ACC 2016

Valve Hemodynamic Deterioration Post-TAVR Is Rare, Not Linked With Adverse Cardiovascular Outcomes

Michael O'Riordan

April 07, 2016

News Conference News ACC 2016

Choosing Radial Over Femoral: Single-Center Study Tackles Questions of When and Why

Yael L. Maxwell

April 06, 2016

News Conference News ACC 2016

Self-Expanding Transcatheter Valve Maintains Advantage Over Surgery at 3 Years in High-Risk Elderly Patients

L.A. McKeown

April 04, 2016

Presentation ACC 2016

Transcatheter or Surgical Aortic Valve Replacement in Intermediate Risk Patients with Aortic Stenosis

Presenter: Craig R. Smith

April 03, 2016

News Conference News ACC 2016

TAVR Mortality Declines as Volumes Increase: So How Many US Centers Are Enough?

Shelley Wood

April 03, 2016

News Conference News ACC 2016

Sapien 3 Superior to Surgery Among Intermediate-Risk Patients in Observational Trial

Yael L. Maxwell

April 03, 2016

Presentation ACC 2016

Relationship Between Procedure Volume and Outcome for Transcatheter Aortic Valve Replacement in U.S. Clinical Practice: Insights from the STS-ACC TVT Registry

Presenter: John D. Carroll

April 03, 2016

Presentation ACC 2016

3-Year Results From the CoreValve US Pivotal High Risk Randomized Trial Comparing Self-Expanding Transcatheter and Surgical Aortic Valves

Presenter: Michael Deeb

April 03, 2016

News Conference News ACC 2016

When Chosen Wisely, 90-Year-Olds Do Well After TAVR

Caitlin E. Cox

April 02, 2016

News Conference News ACC 2016

TAVR With Sapien XT Noninferior to Surgery in Intermediate-Risk Patients, With a Win for Transfemoral

Shelley Wood

April 02, 2016

News Conference News ACC 2015

ACC-i2 2015: Strategies to Enhance PCI Results, TAVR Highlighted

Todd Neale

March 20, 2015

News Conference News ACC 2015

DEFLECT III: TAVR Neuroprotection Device Safely Reduces Lesion Volume

Yael L. Maxwell

March 16, 2015

News Conference News ACC 2015

BEST: Due to Less TVR, CABG Still Favored Over PCI in Patients with Multivessel Disease

L.A. McKeown

March 16, 2015

News Conference News ACC 2015

Thirty-day Outcomes with Sapien 3 Lowest Seen with Balloon-Expandable TAVR

Yael L. Maxwell

March 15, 2015

News Conference News ACC 2015

Follow-up TAVR Studies Reassure About Valve Durability, Outcomes

Todd Neale

March 15, 2015

Presentation ACC 2015

Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial

Presenter: Michael J. Mack

March 15, 2015

Presentation ACC 2015

Clinical and Echocardiographic Outcomes at 30 Days with the SAPIEN 3 TAVR System in Inoperable, High-Risk and Intermediate-Risk AS Patients

Presenter: Susheel K. Kodali

March 15, 2015

Advertisement

Hot or Not, This Year’s Trials Offer Food for Thought: My Takeaways From ACC 2016

Toker’s Paradox? Marijuana Users Face Lower Short-Term Risks After Acute MI, Study Hints

CABG Beats Medical Therapy in CAD Patients With Severe LV Dysfunction: STICH 10-Year Results

Valve Hemodynamic Deterioration Post-TAVR Is Rare, Not Linked With Adverse Cardiovascular Outcomes

Choosing Radial Over Femoral: Single-Center Study Tackles Questions of When and Why

Self-Expanding Transcatheter Valve Maintains Advantage Over Surgery at 3 Years in High-Risk Elderly Patients

Transcatheter or Surgical Aortic Valve Replacement in Intermediate Risk Patients with Aortic Stenosis

TAVR Mortality Declines as Volumes Increase: So How Many US Centers Are Enough?

Sapien 3 Superior to Surgery Among Intermediate-Risk Patients in Observational Trial

Relationship Between Procedure Volume and Outcome for Transcatheter Aortic Valve Replacement in U.S. Clinical Practice: Insights from the STS-ACC TVT Registry

3-Year Results From the CoreValve US Pivotal High Risk Randomized Trial Comparing Self-Expanding Transcatheter and Surgical Aortic Valves

When Chosen Wisely, 90-Year-Olds Do Well After TAVR

TAVR With Sapien XT Noninferior to Surgery in Intermediate-Risk Patients, With a Win for Transfemoral

ACC-i2 2015: Strategies to Enhance PCI Results, TAVR Highlighted

DEFLECT III: TAVR Neuroprotection Device Safely Reduces Lesion Volume

BEST: Due to Less TVR, CABG Still Favored Over PCI in Patients with Multivessel Disease

Thirty-day Outcomes with Sapien 3 Lowest Seen with Balloon-Expandable TAVR

Follow-up TAVR Studies Reassure About Valve Durability, Outcomes

Five-Year Outcomes after Randomization to Transcatheter or Surgical Aortic Valve Replacement: Final Results of The PARTNER 1 Trial

Clinical and Echocardiographic Outcomes at 30 Days with the SAPIEN 3 TAVR System in Inoperable, High-Risk and Intermediate-Risk AS Patients

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content